Bionic Power Play: Dual-Targeting MDMX/MDM2 to Reboot p53 to Beat Lung Adenocarcinoma’s Immune Tricks
The E@MDP is a promising strategy for lung cancer immunotherapy and overcomes several limitations of conventional peptide drugs. The bionic nanodrug platform holds great potential for broader applications in cancers characterized by immune evasion.
Authors
- Lu Xu (ORCID: https://orcid.org/0000-0003-0775-7770)
- Solomon Wong
- Weiming You
- Wangxiao He (ORCID: https://orcid.org/0000-0002-2054-6022)
- Zhongquan Qi (ORCID: https://orcid.org/0000-0002-7210-4955)
- X. X. Zheng
Institutions
- Guangxi University (CN)
- Xiamen University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Fuzhou Maternity and Child Health Care Hospital (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/ijn.s533208
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00